Ghana FDA: Orders Arcan Bitters Sildenafil Recall, Shuts Down Manufacturer

• The Ghana Food and Drugs Authority (FDA) ordered a recall of Arcan Bitters due to adulteration with Sildenafil Citrate.
• Unni Associates Company Limited, the manufacturer, was given 14 days to withdraw the product and had its facility in Parkoso, Ashanti Region, shut down.
• Laboratory tests confirmed Sildenafil Citrate, a prescription-only PDE5 inhibitor, in the alcoholic beverage, which was registered with the FDA as an alcoholic product.
• The FDA issued a public notice detailing these findings on Wednesday, September 2, 2026.
• This action highlights the FDA's strict enforcement against food adulteration and non-compliance with product safety regulations in Ghana.

This incident serves as a stark reminder of the Ghana FDA's rigorous enforcement posture regarding food and drug safety standards.

The Ghana Food and Drugs Authority (FDA) has initiated a significant product withdrawal, ordering the recall of Arcan Bitters from the Ghanaian marketplace. This decisive action follows laboratory analyses conducted by the regulatory body, which conclusively revealed that the alcoholic beverage had been illicitly adulterated with Sildenafil Citrate. This substance is a prescription-only medication primarily utilized for treating erectile dysfunction.

In response to these findings, the FDA has mandated that Unni Associates Company Limited, the manufacturer of Arcan Bitters, complete the withdrawal of the compromised product within a strict fourteen-day timeframe. Furthermore, the regulatory body has taken the severe step of shutting down the company's manufacturing facility. This facility is situated in Parkoso, located within the Asokore Mampong Municipality of the Ashanti Region. The comprehensive Ghana FDA Arcan Bitters Sildenafil recall highlights the authority's commitment to public health and safety.

The public notice, issued by the FDA on Wednesday, September 2, 2026, detailed the specific findings that prompted the recall. Laboratory tests performed on samples of Arcan Bitters confirmed the presence of Sildenafil Citrate, despite the product being explicitly registered with the Authority as an alcoholic beverage. The product's labeling indicated an alcohol content of 35% by volume, yet it contained an undeclared pharmaceutical ingredient.

Sildenafil Citrate is classified as a Phosphodiesterase Type 5 (PDE5) inhibitor. Its inclusion in any food product, particularly an alcoholic drink, is strictly prohibited under existing regulations. As a prescription-only drug, its consumption without medical supervision can pose significant health risks, especially for individuals with underlying health conditions or those taking other medications. The Ghana Food and Drugs Authority recall underscores the critical importance of preventing Sildenafil Citrate food adulteration Ghana, as such practices endanger consumers by introducing potent pharmacological agents into unregulated consumables.

This incident serves as a stark reminder of the Ghana FDA's rigorous enforcement posture regarding food and drug safety standards. The immediate Unni Associates Company Limited shutdown and the mandated product withdrawal demonstrate the severe consequences awaiting manufacturers who fail to adhere to ingredient declaration protocols and product safety regulations. The presence of a powerful prescription drug in a widely available alcoholic beverage represents a serious breach of public trust and regulatory compliance.

Manufacturers and distributors operating within Ghana are under an obligation to ensure the integrity and safety of their products. Strict adherence to ingredient declarations and the complete absence of unauthorized substances are non-negotiable requirements. The Ghana product withdrawal regulations are designed to protect consumers from adulterated goods, and the FDA's swift response in this case reinforces its commitment to upholding these standards. This action sends a clear message across the industry that product adulteration will result in significant penalties, including operational closures and widespread recalls, emphasizing the necessity for meticulous quality control and ethical manufacturing practices.

This incident underscores the Ghana FDA's strict enforcement of food and drug safety regulations, particularly against product adulteration. Manufacturers and distributors in Ghana must ensure rigorous compliance with ingredient declarations to avoid severe penalties like product recalls and facility shutdowns.

Source: Original reporting via Carbonatix